Abstract: Objective 　With taxotere as a control, to evaluate the efficacy, toxicity and CBR of domestic docetaxel-based combination chemotherapy in the treatment of metastatic breast cancer. Methods 　Fourteen metastatic breast cancer patients without anthracycline2pret reated were t reated with docetaxel and doxorubicin (A1) and sixteen metastatic breast cancer patients with anthracycline-pret reated were treated with docetaxel and capecitabine (A2) . Eleven metastatic breast cancer patients without anthracycline-pret reated were treated with taxotere and doxorubicin (B1) and fourteen metastatic breast cancer patients with anthracycline-pret reated were treated with taxotere and capecitabine (B2) . Every 3 weeks a cycle. Efficacy, toxicity and CBR were recorded in every 2 cycles. Results 　Fif ty - five patients were evaluated. The response rate was 66. 7 % and 68 %. The tumor cont rol rate was 93. 3 % and 92 %. The main toxicities were bone marrow suppression and alopecia, and were tolerable. The CBR was 73. 3 % and 72 %. There was no significant difference between treated group and control group. Conclusion 　Domestic docetaxel-based combination chemotherapy is effective for metastatic breast cancer. It is well-tolerated and well-clinical benefit responsed.